Merck KGaA, a Darmstadt, Germany-based pharmaceutical company, is hoping AI can improve its ability to predict drug shortages and plan accordingly.
The company says its current methods for forecasting supply and demand are 85% accurate, according to a new report from The Wall Street Journal, and it hopes AI can provide much more accuracy.
“The value is going to be that every single patient will receive the drug that he or she needs at the right moment,” said Alessandro DeLuca, CIO for Merck’s healthcare division, as quoted by the WSJ.
Merck is turning to TraceLink, a North Reading, Massachusetts-based supply chain company, to see if AI can make an impact. Merck plans on testing TraceLink’s cloud-based software platform later in 2019.
Click the link below for the full story.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.